INMB
INmune Bio, Inc.NASDAQHealthcare$1.21+1.65%ClosedMarket Cap: $32.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.39
P/S
654.00
EV/EBITDA
-0.29
DCF Value
$0.76
FCF Yield
-74.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-94766.0%
Net Margin
-91866.0%
ROE
-171.0%
ROA
-142.0%
ROIC
-188.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-5.5M | $-5.3M | $1.72 | — |
| FY 2025 | $50.0K | 100.0% | $-30.9M | $-45.9M | $0.00 | — |
| Q3 2025 | $0.00 | -Infinity% | $-7.4M | $-6.5M | $-0.24 | — |
| Q2 2025 | $0.00 | NaN% | $-24.6M | $-24.5M | $-1.05 | — |
| Q1 2025 | $50.0K | 100.0% | $-9.9M | $-9.7M | $-0.43 | — |
| Q4 2024 | $0.00 | NaN% | $-9.5M | $-9.2M | $-0.41 | — |
| FY 2024 | $14.0K | 100.0% | $-42.6M | $-42.1M | $-2.11 | — |
| Q3 2024 | $0.00 | NaN% | $-12.3M | $-12.1M | $-0.60 | — |
| Q2 2024 | $0.00 | NaN% | $-9.9M | $-9.7M | $-0.50 | — |
| Q1 2024 | $14.0K | 100.0% | $-11.0M | $-11.0M | $-0.61 | — |
| Q4 2023 | $28.0K | 100.0% | $-8.4M | $-8.4M | $-0.47 | — |
| FY 2023 | $155.0K | 100.0% | $-29.7M | $-30.0M | $-1.67 | — |